Net loss (USD, thousands)

Bargain purchase gain (USD, thousands)

Stock-based compensation expense (USD, thousands)

Amortization of acquired intangible assets (USD, thousands)

Depreciation and amortization (USD, thousands)

Accretion of discount on short-term investments, net (USD, thousands)

Non-cash lease expense (USD, thousands)

Provision for excess and obsolete inventory (USD, thousands)

Change in fair value of warrants (USD, thousands)

Other non-cash items (USD, thousands)

Net cash used in operating activities (USD, thousands)

Purchases of short-term investments (USD, thousands)

Proceeds from sales and maturities of investments (USD, thousands)

Purchases of property and equipment (USD, thousands)

Net cash provided by (used in) investing activities (USD, thousands)

Repayment of term loan and convertible notes (USD, thousands)

Payment of term loan fee (USD, thousands)

Repurchase of common stock (USD, thousands)

Payments for taxes related to net share settlement of equity awards and other (USD, thousands)

Proceeds from exercise of stock options (USD, thousands)

Net cash provided by (used in) financing activities (USD, thousands)

Effect of foreign exchange rate fluctuations on cash and cash equivalents (USD, thousands)

Net increase (decrease) in cash, cash equivalents and restricted cash (USD, thousands)

Cash and restricted cash acquired in the Merger (USD, thousands)

Cash, cash equivalents and restricted cash at beginning of period (USD, thousands)

Cash, cash equivalents and restricted cash at end of period (USD, thousands)

f449359c7533f0cd5c167f262bacbad73f65c9c89f7de1441af0c761577a1ac5

Cash and cash equivalents (USD, thousands)

Short-term investments (USD, thousands)

Accounts receivable, net (USD, thousands)

Inventory, current (USD, thousands)

Prepaid expenses and other current assets (USD, thousands)

Total current assets (USD, thousands)

Inventory, non-current (USD, thousands)

Property and equipment, net (USD, thousands)

Operating lease right-of-use asset, net (USD, thousands)

Other non-current assets (USD, thousands)

Acquired intangible assets, net (USD, thousands)

Goodwill (USD, thousands)

Total assets (USD, thousands)

Accounts payable (USD, thousands)

Accrued liabilities (USD, thousands)

Operating lease liabilities, current (USD, thousands)

Deferred revenue, current (USD, thousands)

Deferred grant income, current (USD, thousands)

Total current liabilities (USD, thousands)

Convertible notes, non-current (USD, thousands)

Deferred tax liability (USD, thousands)

Operating lease liabilities, non-current (USD, thousands)

Deferred revenue, non-current (USD, thousands)

Deferred grant income, non-current (USD, thousands)

Other non-current liabilities (USD, thousands)

Total liabilities (USD, thousands)

Total stockholders’ equity (deficit) (USD, thousands)

Total liabilities, mezzanine equity and stockholders’ equity (deficit) (USD, thousands)

24780928c4a2260f3996451deec8b05e47b955ecab50ce322cee24984794354b

Adjustments for Non-Cash Items (USD, thousands)

Stock-Based Compensation (USD, thousands)

Changes in Working Capital (USD, thousands)

Capital Expenditures (CapEx) (USD, thousands)

Proceeds from / Repayments of Debt (USD, thousands)

Share Repurchases (USD, thousands)

Dividend Payments (USD, thousands)

Net Change in Cash (USD, thousands)

3cc6e368ae853614b4d1a3ddac8d1f677ec56aab7906d3560ba8668841592bb7

Proteomics

Genomics

Instruments

Consumables

- SomaScan Assay Kits

Lab Services

- Assay Services

- Field Services

Collaboration & Other

Total Revenue

dadf9781d7fe3ed3e30c4e2713e62b3820dddfc550d992e64124710a2ba735e1

Number of protein measurements for the SomaScan 11K platform (measurements)

Minimum sample volume for the SomaScan 11K platform (µl)

93a1fd6527ff9c297cefb3626f8a3564c66d016a505450aaaa5ead81424d914d

Total Revenue (USD, thousands)

Cost of Goods Sold (COGS) (USD, thousands)

SG&A (USD, thousands)

R&D (USD, thousands)

D&A (USD, thousands)

Interest Expense (USD, thousands)

Operating Income (EBIT) (USD, thousands)

Net Income (USD, thousands)

EPS - Basic (USD)

EPS - Diluted (USD)

0a8d5bffc65190702a5b594ddedf232d91f2b70dc92712897f3284892476009f

Current Assets (USD, thousands)

Cash and Cash Equivalents (USD, thousands)

Accounts Receivable (USD, thousands)

Inventory (USD, thousands)

Non-Current Assets (USD, thousands)

Property, Plant, and Equipment (PP&E) (USD, thousands)

Intangible Assets (USD, thousands)

Current Liabilities (USD, thousands)

Accounts Payable (USD, thousands)

Short-term Debt (USD, thousands)

Accrued Expenses (USD, thousands)

Non-Current Liabilities (USD, thousands)

Long-term Debt (USD, thousands)

Lease Liabilities (USD, thousands)

Deferred Tax Liabilities (USD, thousands)

Shareholders' Equity (USD, thousands)

Retained Earnings (USD, thousands)

Common Stock (USD, thousands)

Additional Paid-in Capital (USD, thousands)

635c9e17ff0c79c93cd434a47ee56fefb4f339b81545ab14a399f402c31fd26a

Product Revenue (USD, thousands)

Service Revenue (USD, thousands)

Collaboration and Other Revenue (USD, thousands)

Cost of Product Revenue (USD, thousands)

Cost of Service Revenue (USD, thousands)

Cost of Collaboration and Other Revenue (USD, thousands)

Total Cost of Revenue (USD, thousands)

Gross Profit (USD, thousands)

Research and Development Expenses (USD, thousands)

Selling, General and Administrative Expenses (USD, thousands)

Restructuring and Related Charges (USD, thousands)

Transaction and Integration Expenses (USD, thousands)

Total Operating Expenses (USD, thousands)

Loss from Operations (USD, thousands)

Bargain Purchase Gain (USD, thousands)

Interest Income (USD, thousands)

Other (Expense) Income, Net (USD, thousands)

Loss Before Income Taxes (USD, thousands)

Income Tax (Expense) Benefit (USD, thousands)

Net Loss (USD, thousands)

Induced Conversion of Redeemable Preferred Stock (USD, thousands)

Net Loss Attributable to Common Stockholders (USD, thousands)

Net Loss Per Share Attributable to Common Stockholders, Basic and Diluted (USD)

Shares Used in Computing Net Loss Per Share Attributable to Common Stockholders, Basic and Diluted (thousands)

444a2f46eb77df2c024d328882582183b39a879e12509982b471207c8bfcf739

Standard BioTools Inc (LAB)

Financials